Results 81 to 90 of about 29,860 (191)

Advances in Human Mass Balance Studies: An IQ Consortium Perspective on Current Practices and Emerging Trends

Clinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 43-54, July 2026.
Human radiolabeled mass balance studies are crucial for comprehensively characterizing the absorption, distribution, metabolism, and excretion (ADME) of investigational drugs, providing essential data for drug development, regulatory evaluation, and product labeling.
Jason Boer, Ellen Cannady, Filip Cuyckens, Ulrike Glaenzel, Camille Granvil, Felix Huth, Alexander D. James, Wenying Li, Céline Veau, Graeme Young, Qin Yue, Gregory S. Walker, Upendra A. Argikar, Jonathan N. Bauman, Cathy Cantalloube, Yu‐Luan Chen, Ping Kang, Patricia Moliner, Mette L. Pedersen, Isabel Piel, Simone Schadt, Hanno Schieferstein, Julia Suchomel, Shuai Wang, S. Cyrus Khojasteh   +24 more
wiley   +1 more source

Remission spectroscopy resolves the mechanism of action of bedaquiline within living mycobacteria

Nature Communications
Bedaquiline, an ATP synthase inhibitor, is the spearhead of transformative therapies against drug-resistant Mycobacterium tuberculosis. Here, we use remission spectroscopy to measure the energy-transducing cytochromes within unperturbed, respiring ...
Suzanna H. Harrison, Rowan C. Walters, Chen-Yi Cheung, Roger J. Springett, Gregory M. Cook, Morwan M. Osman, James N. Blaza   +6 more
doaj   +1 more source

Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations

, 2016
Minhui Hu,1 Chunlan Zheng,1 Feng Gao2 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of ...
Zheng CL, Hu MH, Gao F
core  

Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China

BMC Infectious Diseases, 2020
Background Currently available injectable agents are inadequate to address the high drug-resistant tuberculosis (DR-TB) burden in China. Regimens including the oral agent bedaquiline have been shown to be efficacious and safe, leading to its ...
Abela Mpobela Agnarson, Xiao Chun Wang, Ravi Potluri, Hitesh Bhandari, Amit Dhir, Chrispin Kambili, Laurent Metz   +6 more
doaj   +1 more source

Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline

, 2014
BACKGROUND Bedaquiline (Sirturo, TMC207), a diarylquinoline that inhibits mycobacterial ATP synthase, has been associated with accelerated sputum-culture conversion in patients with multidrug-resistant tuberculosis, when added to a preferred background ...
Meyvisch, Paul, de Los Rios, Jorge M., Grobusch, Martin P., Dannemann, Brian, Gotuzzo, Eduardo, Haxaire-Theeuwes, Myriam, Andries, Koen, Bakare, Nyasha, Diacon, Andreas H., de Paepe, Els, Pym, Alexander, Leimane, Vaira, van Heeswijk, Rolf P. G., Vasilyeva, Irina, de Marez, Tine, Lounis, Nacer   +15 more
core   +1 more source

Determination of Bedaquiline in Human Serum Using Liquid Chromatography-Tandem Mass Spectrometry [PDF]

, 2015
Bedaquiline, a diarylquinoline for the treatment of multidrug-resistant tuberculosis (TB), relies on exposure-dependent killing. As data on drug exposure in specific populations are scarce, pharmacokinetic studies may be of interest. No simple and robust
Bolhuis, Mathieu, Alffenaar, Jan-Willem C., Akkerman, Onno; id_orcid, Akkerman, Onno, Greijdanus, Ben, Touw, Daan; id_orcid, van Hateren, Kai, Touw, Daan, Sturkenboom, Marieke, Sturkenboom, Marieke; id_orcid, de Lange, Wiel, van der Werf, Tjip   +11 more
core   +2 more sources

Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies

Pharmaceutics, 2019
Bedaquiline is a newly developed anti-tuberculosis drug, conditionally approved by the United States Food and Drug Administration (USFDA) for treating drug-resistant tuberculosis in adults.
Mohammad A. M. Momin, Bhamini Rangnekar, Shubhra Sinha, Chen-Yi Cheung, Gregory M. Cook, Shyamal C. Das   +5 more
doaj   +1 more source

Effectiveness and safety of regimen containing bedaquiline and delamanid in patients with drug-resistant tuberculosis

Perspectives in Clinical Research
Background: Bedaquiline and delamanid have been included in the individualized treatment regimen (ITR) to treat patients with drug-resistant tuberculosis (DR-TB).
Oki Nugraha Putra, Yulistiani Yulistiani, Soedarsono Soedarsono, Susi Subay   +3 more
doaj   +1 more source

Peran bedaquiline untuk tuberkulosis resisten obat: A literature review [PDF]

Background: Multidrug-resistant tuberculosis (MDR/RR-TB) is a serious challenge in global TB elimination efforts. Indonesia as a country with a high TB ​​burden faces the problem of MDR/RR-TB therapy, where the effectiveness of second-line treatment is ...
Darmanto, Arief Gunawan, Dewi, Desak Nyoman Surya Suameitria   +1 more
core   +1 more source

Linking genetic and phenotypic bedaquiline resistance in Mycobacterium tuberculosis strains from Georgia.

PLoS ONE
IntroductionResistance to bedaquiline - a novel, promising medication against tuberculosis (TB), is already emerging, and uncertainties regarding the role of the different resistance-conferring mutations complicate the development of molecular diagnostic
Nino Maghradze, Chloé Loiseau, Galo Adrian Goig, Nino Bablishvili, Levan Jugheli, Sonia Borrell, Nestani Tukvadze, Russell Ryan Kempker, Zaza Avaliani, Sebastien Gagneux   +9 more
doaj   +1 more source